Supplementary table 1: clinical information regarding LT

Supplementary table 1: clinical information regarding LT

Control with LT AS ddNAS pNAS

Indicatio n for LT

Alcoholic cirrhosis (50 %), Chronic HCV infection (25

%), primary

hyperoxaluria (25 %)

Chronic HCV infection (35.5 %), alcoholic cirrhosis (22.6 %), chronic HBV infection (12.9 %), Cryptogenic cirrhosis (12.9 %), PSC (3.2 %), Others (toxic cirrhosis, early transplant failure, congenital hepatic fibrosis,

amylodiosis) (12.9

%)

Alcoholic cirrhosis (26.9 %), Chronic HCV infection (15.4 %), Immunological liver disease (PSC- AIH, AIH) (15.4

%), Chronic HBV infection (7.7 %), NASH (7.7 %), Cryptogenic cirrhosis (7.7 %), Others (PFIC-3, toxic cirrhosis, early transplant failure,

amyloidosis ) (19.2

%)

Alcoholic cirrhosis (54.5 %), Chronic HCV infection (18.2 %), Chronic HBV infection (9.1

%),

Cryptogenic cirrhosis (9.1 %), Others (toxic cirrhosis) (9.1 %)

Time after LT

11 ± 13 24 ± 38 33 ± 51 6 ± 8

Cold ischemia time

12.0 10.0 ± 2.8 10.9 ± 2.5 12.4 ± 3.0

Indication for LT are shown in percentage, time from LT to ERC are presented in months and

cold ischemia time in hours. Months and hours are expressed in mean ± SD. Values for cold

ischemia time were missing in 47% of cases.